Menlo Therapeutics Inc., of Menlo Park, Calif., said a phase II trial (TCP-102) evaluating serlopitant to treat pruritus (itch) associated with prurigo nodularis met its primary efficacy endpoint and key secondary endpoints, demonstrating a statistically significant reduction in pruritus (p